Skip to content

Call Us Today: 812-689-0791

info@neuraxis.com

812-689-0791

info@neuraxis.com

NeurAxis
NeurAxis
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact

PENFS

35 items

  • Press Release

    May 22, 2024

    NeurAxis Reports First Quarter 2024 Financial Results

    CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 21, 2024

    NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

    CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 16, 2024

    NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida

    CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 15, 2024

    NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

    CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    April 23, 2024

    NeurAxis Announces New Medical Policy Coverage in North Dakota

    CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    April 9, 2024

    NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

    CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    April 1, 2024

    NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

    CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    March 27, 2024

    NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry

    CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    March 11, 2024

    NeurAxis Announces Highmark BCBS Policy Coverage

    CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
  • Press Release

    March 4, 2024

    NeurAxis Announces New Medical Policy Coverage Adding 1 Million Covered Lives

    CARMEL, Ind., March 4, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:

    Continue reading
Previous234Next
NeurAxis
(812) 689-0791
info@neuraxis.com

Quick Links

  • Home
  • IB-Stim
  • RED
  • Investor Relations
  • Home
  • IB-Stim
  • RED
  • Investor Relations

About NeurAxis

  • About
  • Our Team
  • Patents
  • Contact Us
  • About
  • Our Team
  • Patents
  • Contact Us

Sign up for News

© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
Page load link
Go to Top